GH Research (NASDAQ:GHRS) Stock Price Up 0.2% – Still a Buy?

GH Research PLC (NASDAQ:GHRS) traded up 0.2% on Thursday . The company traded as high as $9.70 and last traded at $9.26. 22,329 shares changed hands during trading, a decline of 72% from the average session volume of 78,940 shares. The stock had previously closed at $9.24.

Wall Street Analysts Forecast Growth

GHRS has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of GH Research in a report on Thursday, September 5th. JMP Securities restated a “market outperform” rating and set a $39.00 target price on shares of GH Research in a research report on Wednesday, September 4th.

GH Research Price Performance

The business’s fifty day simple moving average is $7.74 and its 200 day simple moving average is $10.39. The firm has a market capitalization of $460.47 million, a price-to-earnings ratio of -13.82 and a beta of 0.74.

GH Research (NASDAQ:GHRS) last announced its quarterly earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.03. Equities research analysts expect that GH Research PLC will post -0.85 earnings per share for the current fiscal year.

Institutional Trading of GH Research

An institutional investor recently raised its position in GH Research stock. Lynx1 Capital Management LP grew its holdings in shares of GH Research PLC (NASDAQ:GHRS) by 80.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,310,563 shares of the company’s stock after buying an additional 1,471,946 shares during the quarter. GH Research accounts for about 9.1% of Lynx1 Capital Management LP’s holdings, making the stock its 6th biggest position. Lynx1 Capital Management LP owned approximately 6.36% of GH Research worth $35,291,000 as of its most recent SEC filing. 56.90% of the stock is owned by institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).